Parallax Volatility Advisers
IBRX icon

Parallax Volatility Advisers’s ImmunityBio IBRX Stock Holding History

Parallax Volatility Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,000
Closed -$38.9K – 2427
2023
Q2 		$38.9K Buy
14,000
+100
+0.7% +$283 ﹤0.01% 2091
2023
Q1 		$25.3K Buy
+13,900
New +$43.2K ﹤0.01% 2298

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Parallax Volatility Advisers's IBRX Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of ImmunityBio (IBRX) in Q3 2023, closing a stake of 297 shares — an estimated $826 sold.

Parallax Volatility Advisers first reported a position in IBRX in Q4 2017 and held it in 2 quarters. The position peaked at $21K in Q4 2017. 131 funds tracked by Wall St. Rank hold IBRX as of Q3 2023.

  • Parallax Volatility Advisers reported no remaining ImmunityBio position as of Q3 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 297 ImmunityBio shares in Q3 2023, an estimated $826.
  • Parallax Volatility Advisers first reported a position in ImmunityBio in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's ImmunityBio position peaked at $21K in Q4 2017.
  • 131 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.